gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MGXHealthcareBiotechnology

Metagenomi Therapeutics, Inc. Common Stock (MGX)

$0.7308−7.49%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$0.73▼ 67.66% in range
Nov 5, 2025Low $0.73 · High $2.26Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

Metagenomi Therapeutics closed at $0.73 on Nov 5, down 7.49%, within 0.0% of its 52-week closing low. Volume of 117.7K shares was 0.75× its 20-day average (below normal).

Split-adjusted performance: -25.8% over one month, -48.5% over six months, -68.1% over one year.

In the quarter ended Jun 30, 2026, revenue was -$257K, down 103.0% from a year earlier.

Short interest was 1.3M shares at the Oct 15 settlement, up 1.6% from the prior report (5.2% of float, 6.3 days to cover).

Market cap$27.6M37.8M shares
Revenue · quarter-$257.0K−103.0% YoY
Diluted EPS$-0.73—
P/E · TTM—P/S 2.0×
Net margin—
Dividend yieldNone
52-week range0.73 – 2.29−68.1% from high
Volume117.7K0.75× 20-day avg
Volatility · 60d49.8%Annualised
Short % of float5.2%6.3 days to cover
Net cash$120.7MCash $120.7M
Next earnings—Not scheduled
Split-adjusted performance
1W −12.0%1M −25.8%3M −40.6%6M −48.5%YTD −54.9%1Y −68.1%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum31
Revenue growth0
Net margin—
Value (low P/E)—
Size18

Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.

Short interest

Details →
Shares short1.3M+1.6% vs prior
Days to cover6.3Settled Oct 15
% of float5.2%
Short vol. 10d40.2%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MGXMetagenomi Therapeutics$0.7308−7.49%−48.5%−103.0%——$27.6M
ALGSAligos Therapeutics$4.51−10.16%−25.2%+2778.5%−5.4%—$28.2MCompare
CVMCel-Sci$1.37−0.72%−14.4%———$24.1MCompare
ELUTElutia$0.7509−1.15%−24.8%−11.6%−315.0%0.6$33.3MCompare
INMBINmune Bio$1.18−11.65%−17.8%———$36.4MCompare
PTHSPelthos Therapeutics$9.30−8.37%−62.8%—−150.1%—$36.6MCompare
EXOZeXoZymes$4.11−4.64%−58.9%———$38.2MCompare
BSEMBioStem Technologies$1.04−9.57%————$19.4MCompare
BKHABlack Hawk Acquisition$4.50−19.21%————$18.7MCompare

News about Metagenomi Therapeutics

All news →
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare ConferenceGlobeNewswire Inc. · Sep 1, 2026▲ PositiveMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing EfficiencyGlobeNewswire Inc. · Apr 16, 2026▲ Positive

Quick answers

What does Metagenomi Therapeutics do?
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems.
What is MGX's market cap?
$27.61M, based on the Nov 5 close of $0.73.
Does Metagenomi Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MGX is sold short?
1.3M shares, 5.2% of float, as of Oct 15, 2026.
What sector is MGX in?
Healthcare, in the Biotechnology industry.

About Metagenomi Therapeutics

Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.

HQ: Emeryville, CA113 employeesListed Feb 9, 2024metagenomi.co

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology